Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 48Neoplasm Metastasis 11Hereditary Sensory and Autonomic Neuropathies 7Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Ovarian Neoplasms 5Neoplasms 5Triple Negative Breast Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Lymphangioma 3Hyperglycemia 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Head and Neck Squamous Cell Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Breast Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × Alpelisib × Clear all
NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT02051751 2020-12-08

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Novartis

Phase 1 Completed
19 enrolled
BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Novartis

Phase 1 Completed
79 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡